Currently, Iovance Biotherapeutics Inc [IOVA] is trading at $1.78, up 1.71%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IOVA shares have gain 7.23% over the last week, with a monthly amount drifted -47.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on May 16, 2025, when UBS downgraded its rating to a Neutral but kept the price target unchanged to $2 for it. Previously, Truist downgraded its rating to Hold on May 12, 2025. On May 09, 2025, downgrade downgraded it’s rating to Mkt Perform. UBS started tracking the stock assigning a Buy rating and suggested a price target of $17 on October 24, 2024. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $10 on July 29, 2024. Goldman started tracking with a Buy rating for this stock on November 20, 2023, and assigned it a price target of $12. In a note dated September 18, 2023, Barclays reiterated an Overweight rating on this stock and revised its target price from $40 to $18.
This stock has fluctuated between a low of $1.64 and a high of $12.51 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $1.78 at the most recent close of the market. An investor can expect a potential return of 124.72% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Trailing Twelve Months sales for Iovance Biotherapeutics Inc [NASDAQ:IOVA] were 212.68M which represents 6798.46% growth. Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -1.88%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7033 points at the first support level, and at 1.6267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8233, and for the 2nd resistance point, it is at 1.8667.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Iovance Biotherapeutics Inc [NASDAQ:IOVA] is 4.18. Further, the Quick Ratio stands at 3.64, while the Cash Ratio is 1.4. Considering the valuation of this stock, the price to sales ratio is 2.79, the price to book ratio is 0.77.
Transactions by insiders
Recent insider trading involved Vogt Frederick G, Interim CEO & General Counsel, that happened on May 14 ’25 when 25000.0 shares were purchased. Director, Maynard Ryan D completed a deal on Nov 12 ’24 to sell 50000.0 shares. Meanwhile, Director Maynard Ryan D bought 50000.0 shares on Nov 12 ’24.
